References
- TASK FORCE OF THE WORKING GROUP ON ARRHYTH-MIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY: CAST and beyond: implications of the Cardiac Arrhyth-mia Suppression Trial. Circulation (1990) 49:1123.
- Scrip (1994) 1973:24.
- Scrip (1994) 1985:25.
- ARCHIBALD DG, QUART B, HARDY S, MACNEIL DJ, LEHMANN MH: Torsade de pointes with sotalol: relation-ship of gender to risk J. Am. Coll. Cardiol. (1994) 23:279A.
- Scrip (1994) 1953:22.
- Scrip (1992) 1713:22.
- SINGH SN, FLETCHER RD, FISHER SG, LEWIS P, DEED-WANIA PC, MASSIE BM, SINGH BN, COLLINGS CL, CHFSTAT INVESTIGATORS: Results of the congestive heart failure survival trial of antiarrhythmir therapy. Circulation (1994) 90(Suppl. I):546.
- JULIAN DG, JACKSON FS, PRESCOYTT FJ, SZEKLEY P:Control trial of sotalol for one year after myocardial Infarction. Lancet (1982) 1:1142–1147.
- MIURA DS, FRISHMAN WH, DANGMAN KH: Class II drugs.In: Electrophysiology and Pharmacology of the Heart, A Clinical Guide. Dangman ICH, Miura DS (Eds.). Marcal Decker, Inc. (1991):665.
- THomis J, TENTHOREY P: Prolonged ventricular repo-larisation - A prevention of severe arrhythmias? Annual Reports in Medicinal Chemistry (1983) 18:99.
- STEINBERG MI, LACEFIELD WM, ROBERTSON DW: Class I and III antiarrhythmic drugs. Annual Reports in Medicinal Chemistry (1986) 21:95.
- ARGENTIERI TM, SULLIVAN ME, WIGGINS JR: Class III antiarrhythmic agents. In: Elect rophysiology and Pharma-cology of the Heart, A Clinical Guide. Dangman ICH, Miura DS (Eds.). Marcel Decker, Inc. (1991):677.
- CIMINI MG, GIBSON JK: Recent advances in antiarrhythink therapy. Potassium channel antagonists. Annual Reports in Medicinal Chemistry (1992) 27:89.
- This is a particularly useful review of the Class III agents from a structural perspective and also provides a good introduction to the antiarrhythmic area.
- PRIMEAU J: Curr. Opin. Invest Drugs (1993) 2(10):1127.
- LAZARRA R: Antiarrhythmic drugs and torsade de poin-tes. Eur. Heart J. (1993) 4(Suppl. H):88.
- FAIVRE JF, FOREST MC, CHEVAL B, GOUT B, LINEE P, RUFFOLO RR, POYSER RH, BRIE A: Electrophysiological activity of BRL-32872, a new class m antiarrhythmic agent with calcium channel antagonist properties. EASES J. (1994) 8A78.
- BRIL A, FAIVRE JF, LANDAIS L, FOREST MC, GOUT B, LINEEP, RUFFOLO RR, POYSER RH: Effect of BRL-32872, a new class III antiarrhythmic agent, on the susceptibility to experimentally-induced triggered arrhythmias. FASEB J (1994) 8:A79.
- GOUT B, BONHOMME M, FAIVRE JF, LINEE P, POYSER RH,RUFFOLO RR: Antifibrillatory effect of BRL-32872, a class M antiarrhythmic agent with calcium antagonist prop-erties, in dogs with chronic myocardial infarction. FASEB J. (1994) 8:A78.